Erytech Pharma SA - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Erytech Pharma SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Erytech Pharma SA - Product Pipeline Review - 2014', provides an overview of the Erytech Pharma SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Erytech Pharma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Erytech Pharma SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Erytech Pharma SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Erytech Pharma SA's pipeline products

Reasons to buy

- Evaluate Erytech Pharma SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Erytech Pharma SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Erytech Pharma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Erytech Pharma SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Erytech Pharma SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Erytech Pharma SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Erytech Pharma SA Snapshot 5
Erytech Pharma SA Overview 5
Key Information 5
Key Facts 5
Erytech Pharma SA - Research and Development Overview 6
Key Therapeutic Areas 6
Erytech Pharma SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Erytech Pharma SA - Pipeline Products Glance 11
Erytech Pharma SA - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Erytech Pharma SA - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Erytech Pharma SA - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Erytech Pharma SA - Drug Profiles 16
asparaginase 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Cell therapy for Phenylketonuria 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Enhoxy 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ERY-MET 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ERY-VAX 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Cell Therapy 2 for Cancer 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Erytech Pharma SA - Pipeline Analysis 23
Erytech Pharma SA - Pipeline Products by Target 23
Erytech Pharma SA - Pipeline Products by Route of Administration 24
Erytech Pharma SA - Pipeline Products by Molecule Type 25
Erytech Pharma SA - Pipeline Products by Mechanism of Action 26
Erytech Pharma SA - Recent Pipeline Updates 27
Erytech Pharma SA - Dormant Projects 31
Erytech Pharma SA - Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Erytech Pharma SA, Key Information 5
Erytech Pharma SA, Key Facts 5
Erytech Pharma SA - Pipeline by Indication, 2014 8
Erytech Pharma SA - Pipeline by Stage of Development, 2014 9
Erytech Pharma SA - Monotherapy Products in Pipeline, 2014 10
Erytech Pharma SA - Phase III, 2014 11
Erytech Pharma SA - Phase II, 2014 12
Erytech Pharma SA - Phase I, 2014 13
Erytech Pharma SA - Preclinical, 2014 14
Erytech Pharma SA - Discovery, 2014 15
Erytech Pharma SA - Pipeline by Target, 2014 23
Erytech Pharma SA - Pipeline by Route of Administration, 2014 24
Erytech Pharma SA - Pipeline by Molecule Type, 2014 25
Erytech Pharma SA - Pipeline Products by Mechanism of Action, 2014 26
Erytech Pharma SA - Recent Pipeline Updates, 2014 27
Erytech Pharma SA - Dormant Developmental Projects,2014 31